Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial

Oliva, Fabrizio; Latini, Roberto; Politi, Alessandro; Staszewsky, Lidia; Maggioni, Aldo P.; Nicolis, Enrico; Mauri, Francesco

doi:10.1016/s0002-8703(99)70108-0

Cited by 136 publications

(67 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…536 Intermittent outpatient infusions of either vasoactive drugs such as nesiritide or positive inotropic drugs have not shown to improve symptoms or survival in patients with advanced HF. 536,545,546 …”

Section: Intravenous Peripheral Vasodilators and Positive Inotropic Amentioning

confidence: 99%

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Hunt¹,

Abraham²,

Chin³

et al. 2009

Circulation

1,930

757

View full text Add to dashboard Cite

Section: Intravenous Peripheral Vasodilators and Positive Inotropic Amentioning

confidence: 99%

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Hunt¹,

Abraham²,

Chin³

et al. 2009

Circulation

1,930

757

View full text Add to dashboard Cite

“…220 Intermittent outpatient infusions of either vasoactive drugs such as nesiritide or positive inotropic drugs have not shown to improve symptoms or survival in patients with advanced HF. 220,230,231 …”

Section: Intravenous Peripheral Vasodilators and Positive Inotropic Amentioning

confidence: 99%

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

Jessup¹,

Abraham²,

Casey³

et al. 2009

Circulation

1,320

538

View full text Add to dashboard Cite

“…After application of the inclusion criteria, 14 studies [25][26][27][28][29][30][31][32][33][34][35][36][37][38] including a total of 673 participants were included in the systematic review, and 13 [25,[27][28][29][30][31][32][33][34][35][36][37][38] studies reported mortality data and were included in the meta-analysis. One study reported a change in symptoms and was included in the qualitative synthesis only [26].…”

Section: Resultsmentioning

confidence: 99%

“…General health questionnaire; 43% reduction (control) vs. 40% reduction (dobutamine) Oliva [36] 5 (control) vs. 7 (dobutamine) required hospitalisation for heart failure 1 (dobutamine) showed increased rate of nonsustained VT on Holter Median NYHA class at 6 months; 3 (control) and 2.5 (dobutamine) Wimmer [38] NR 2 (dobutamine) complained of repeated palpitations Nieminen [35] NR 20% (placebo) vs. 35% (dobutamine) reported adverse events including hypertension, tachycardia and arrhythmias 1 (control) vs. 5 (dobutamine) experienced tachycardia Nanas [34] Mean NYHA at 6 months fell from 4 to 2. Given the strengths and limitations of this study, what are the implications for clinicians?…”

Section: Nrmentioning

confidence: 99%

Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials

2011

View full text Add to dashboard Cite

Purpose: Dobutamine is recommended for patients with severe heart failure; however uncertainty exists as to its effect on mortality. This study aims to critically review the literature to evaluate whether dobutamine, compared with placebo or standard care, is associated with lower mortality and a range of secondary outcomes, in patients with severe heart failure. Methods: A systematic review and meta-analysis of randomised controlled trials was performed. PubMed, EMBASE, the Cochrane Central Trials Registry, the metaRegister of Controlled Trials and bibliographies of retrieved articles were searched. Randomised trials comparing dobutamine with placebo or standard care, in human, adult patients with severe heart failure, were included if they reported at least one outcome of interest. Data regarding trial validity, methodological processes and clinical outcomes were extracted, and a meta-analysis was performed. Results: Fourteen studies, with 673 participants, met the inclusion criteria and were included; 13 studies reported mortality. There was minimal heterogeneity (I 2 = 4.5%). The estimate of the odds ratio for mortality for patients with severe heart failure treated with dobutamine compared with standard care or placebo was 1.47 (95% confidence interval 0.98-2.21, p = 0.06).Conclusions: This meta-analysis showed that dobutamine is not associated with improved mortality in patients with heart failure, and there is a suggestion of increased mortality associated with its use, although this did not reach the conventional level of statistical significance. Further research to define the role of dobutamine in treatment of severe heart failure should be a priority.

show abstract

Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial

Cited by 136 publications

References 12 publications

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials

Contact Info

Product

Resources

About